Assignee
REGEN BIOPHARMA INC
US·7 granted patents·16 pending applications·7 citations·filing 2013–2024
Top patents by PatentIndex Score
23 records- 0184US11141471B2Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cellsREGEN BIOPHARMA INC·Filed 2017·Granted Oct 12, 2021·3 cites·13 claims
- 0282US11090332B2Antigen specific mRNA cellular cancer vaccinesREGEN BIOPHARMA INC·Filed 2016·Granted Aug 17, 2021·2 cites·13 claims
- 0376US11241427B2Small molecule modulators of NR2F6 activityREGEN BIOPHARMA INC·Filed 2016·Granted Feb 8, 2022·1 cites·9 claims
- 0476US11053503B2Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibitionREGEN BIOPHARMA INC·Filed 2017·Granted Jul 6, 2021·1 cites·8 claims
- 0570US2025059507A1Generation of Tolerance Promoting CAR-T Cells by Enhancement of NR2F6REGEN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0666US2024093205A1Dual checkpoint inhibitor aptamer based therapeuticsREGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 0765US2024366760A1Activation of survivin-specific immune responses using dendritic cell derived exosomesREGEN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0864US2024024443A1Augmentation of survivin modified mrna vaccine efficacy using dendritic cellsREGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 0963US11655474B2Suppression of pathological angiogenesis by inhibition of NR2F6REGEN BIOPHARMA INC·Filed 2020·Granted May 23, 2023·0 cites·2 claims
- 1063US2024100160A1Enhancement of t cell homing to tumors through augmentation of chemokine responsiveness and activation dependent chemokine secretionREGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1163US2024165204A1Modulation of tumor microenvironment to augment efficacy of immunotherapyREGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1262US2024066126A1Combination therapy of solid tumors using chimeric antigen receptor cells representing adaptive and innate immunityREGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1359US11712474B2Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibitionREGEN BIOPHARMA INC·Filed 2020·Granted Aug 1, 2023·0 cites·19 claims
- 1451US2021403866A1Enhanced dendritic cell immune activation by combined inhibition of nr2f6 with cannibidiolREGEN BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 1551US2021059962A1Stimulation of t regulatory cells by cannabidiol as a means of treating arthritis and autoimmunityREGEN BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 1651US2013309210A1Acceleration of hematopoietic reconstitution by placental endothelial and endothelial progenitor cellsREGEN BIOPHARMA INC·Filed 2013·Application pending·0 cites
- 1749US2014065096A1Cancer therapy by ex vivo activated autologous immune cellsREGEN BIOPHARMA INC·Filed 2013·Application pending·0 cites
- 1849US2015037303A1Cells, compositions, and treatment methods for stimulation of hematopoiesisREGEN BIOPHARMA INC·Filed 2013·Application pending·0 cites
- 1942US2017166896A1Treatment of Liver Cancer through Embolization Depot Delivery of BORIS Gene Silencing AgentsREGEN BIOPHARMA INC·Filed 2016·Application pending·0 cites
- 2042US2016151469A1Immune modulation by tlr activation for treatment of filovirus infections including ebolaREGEN BIOPHARMA INC·Filed 2015·Application pending·0 cites
- 2142US2021317180A1Nr2f6 inhibited chimeric antigen receptor cellsREGEN BIOPHARMA INC·Filed 2016·Application pending·0 cites
- 2240US2016074489A1Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturationREGEN BIOPHARMA INC·Filed 2015·Application pending·0 cites
- 2327US10088485B2Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligandREGEN BIOPHARMA INC·Filed 2015·Granted Oct 2, 2018·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when REGEN BIOPHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →